As I added, it is not about the effect, it is about the possibility of 'unblinding' (by implication). Blinding is an integral part of this type of trial (placebo comparitive). If it is considered that this has been compromised the overall results could be invalidated.
The question is - will the FDA look into this possibility, and if so what will be the decision? Pretty bold just to say "they won't".
[80% of Trof patients reported diarrhoea against 20% of placebo patients. Would the presence of diarrhoea lead a parent/care giver to lean heavily towards the child being on the active arm? (That is, if increased diarrhoea rates became common knowledge between trial parcipitants). Further (if so) would the FDA then consider this to constitute virtual unblinding of the trial?]
I dunno. I hope not, but without further objective discussion, I would not totally discount the possibility.
As I added, it is not about the effect, it is about the...
-
- There are more pages in this discussion • 9,475 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.70 |
Change
-0.310(2.38%) |
Mkt cap ! $1.623B | |||
| Open | High | Low | Value | Volume |
| $12.80 | $12.90 | $12.69 | $5.154M | 403.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 4631 | $12.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.76 | 1060 | 1 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |